Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ind-Swift Laboratories Ltd. ( (IN:INDSWFTLAB) ) has shared an announcement.
Ind-Swift Laboratories Ltd. has disclosed that CARE Ratings Limited, acting as the independent monitoring agency, has issued its report for the quarter ended 31 December 2025 on the company’s preferential issue of equity capital aggregating Rs 314.60 crore. The filing, made in compliance with SEBI regulations on capital issues and listing obligations, confirms that the monitoring process for the deployment and tracking of these preferential issue proceeds is ongoing, underscoring the company’s adherence to regulatory oversight and providing transparency for shareholders and market participants regarding the use of raised funds.
More about Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Ltd. operates in the pharmaceutical sector, focusing on manufacturing and marketing formulations and active pharmaceutical ingredients for domestic and international markets. The company is listed on both BSE and NSE, reflecting its access to capital markets and engagement with a broad base of institutional and retail investors.
Average Trading Volume: 8,272
Technical Sentiment Signal: Strong Buy
Current Market Cap: 9.25B INR
For detailed information about INDSWFTLAB stock, go to TipRanks’ Stock Analysis page.